Risk Minimization Material, as well as the material intended for patients that can become pregnant, is available as paper documents on request by contacting the local representative of BMS on medicalinfo.belgium@bms.com.

Please view the Resources page for more information such as dosing and reconstitution guides.

For medical questions contact the Medical Information Department, via email to: medicalaffairs.belgium@bms.com

For general questions please contact us.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl^®, please refer to the SmPC. View the EU SmPC in English, SmPC in French, SmPC in Dutch.